Author:
Liu Xiangyu,Zhang Song,Shao Lizhi,Sun Caixia,Li Bao,Wei Wei,Ying Zuobin,Liu Zhenyu,Tian Jie
Abstract
<p>The heterogeneous response and prognosis of patients with colorectal cancer (CRC) to standard treatment regimens remains a challenge for clinical management. Individually weak prognostic markers, defined by gene mutations and protein expression, are difficult to apply in routine clinical practice because of their high acquisition cost and mediocre prediction accuracy. Visual evaluation of medical images, including radiology and digital pathology images, is an important part of CRC management. With the rapid development of artificial intelligence (AI), high-dimensional imaging features other than visual information are increasingly being used to develop imaging markers. At different stages of treatment, accurate predictions of treatment response and prognosis may help in selecting patients and tailoring their treatment. Here, we review the current state of AI applied to the medical imaging of CRC and describe its recent progress in short-term response and long-term survival prediction. In addition, we illustrate how these AI-based approaches may affect clinical decision-making. Although few approaches have been applied in routine clinical practice, their results are promising. Finally, we discuss the challenges in applying AI in clinical practice and possible future solutions from three perspectives: model interpretability, model generalizability, and patient privacy protection. This comprehensive assessment underscores the transformative potential of AI in CRC management and emphasizes the need for further exploration and integration into routine clinical workflows.</p>
Publisher
Innovation Press Co., Limited
Reference148 articles.
1. Sung, H., Ferlay, J., Siegel, R.L., et al. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3): 209?249. DOI: 10.3322/caac.21660.
2.
Benson, A.B., Venook, A.P., Al-Hawary, M.M., et al. (2022). Rectal cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw Network 20 (10): 1139�C1167. DOI: 10.6004/jnccn.2022.0051.
3. Keller, D.S., Berho, M., Perez, R.O., et al. (2020). The multidisciplinary management of rectal cancer. Nat Rev Gastroenterol Hepatol 17(7): 414?429. DOI: 10.1038/s41575-020-0275-y.
4. Bosset, J.-F., Collette, L., Calais, G., et al. (2006). Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355(11): 1114?1123. DOI: 10.1056/NEJMoa060829.
5. Roh, M.S., Colangelo, L.H., O��Connell, M.J., et al. (2009). Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 27(31): 5124. DOI: 10.1200/JCO.2009.22.0467.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献